

Khalid M Dousa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8747428/publications.pdf>

Version: 2024-02-01

14
papers

175
citations

1163117

8
h-index

1125743

13
g-index

14
all docs

14
docs citations

14
times ranked

293
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence of Venous Thromboembolism in Critically Ill COVID-19 Patients: Systematic Review and Meta-Analysis. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 598846.	2.4	31
2	Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR <i>Pseudomonas aeruginosa</i> isolates from Qatar. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 3497-3504.	3.0	24
3	Insights into the β -Lactamase, β -Lactamase Inhibitor (BLI)-Transpeptidases and β -Lactamase Inhibitor (BLI)-Carboxypeptidase of <i>Mycobacterium abscessus</i> : Ceftaroline, Imipenem, and Novel Diazabicyclooctane Inhibitors. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	22
4	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid contamination of surfaces on a coronavirus disease 2019 (COVID-19) ward and intensive care unit. <i>Infection Control and Hospital Epidemiology</i> , 2021, 42, 215-217.	1.8	16
5	Impact of Diabetes Mellitus on the Presentation and Response to Treatment of Adults With Pulmonary Tuberculosis in Qatar. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofy335.	0.9	15
6	“One-Two Punch” Synergistic β -Lactam Combinations for <i>Mycobacterium abscessus</i> and Target Redundancy in the Inhibition of Peptidoglycan Synthesis Enzymes. <i>Clinical Infectious Diseases</i> , 2021, 73, 1532-1536.	5.8	15
7	Inhibiting <i>Mycobacterium abscessus</i> Cell Wall Synthesis: Using a Novel Diazabicyclooctane β -Lactamase Inhibitor To Augment β -Lactam Action. <i>MBio</i> , 2022, 13, e0352921.	4.1	13
8	Ibrutinib Therapy and <i>Mycobacterium chelonae</i> Skin and Soft Tissue Infection. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy168.	0.9	12
9	Drug-Resistant Tuberculosis. <i>Infectious Disease Clinics of North America</i> , 2020, 34, 863-886.	5.1	9
10	SARS-CoV-2 infection in a patient on chronic hydroxychloroquine therapy: Implications for prophylaxis. <i>IDCases</i> , 2020, 20, e00778.	0.9	8
11	<i>Mycobacterial Tenosynovitis After Sea Urchin Spine Injury in an Immunocompromised Patient</i> . <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy285.	0.9	3
12	Progressive and disseminated histoplasma infection and hemophagocytic lymphohistiocytosis in an immunocompetent adult. <i>Clinical Case Reports (discontinued)</i> , 2019, 7, 913-916.	0.5	3
13	Renal infarction in vascular Ehlers-Danlos syndrome masquerading as pyelonephritis. <i>Clinical Case Reports (discontinued)</i> , 2018, 6, 1478-1480.	0.5	2
14	1390. Durlabactam, a Diazabicyclooctane (DBO) β -lactamase Inhibitor (BLI), Inhibits BlaC and Peptidoglycan (PG) Transpeptidases of <i>Mycobacterium tuberculosis</i> (Mtb): A Novel Approach to Therapeutics for Tuberculosis (TB)? <i>Open Forum Infectious Diseases</i> , 2021, 8, S780-S780.	0.9	2